-

Calix, Inc. Securities Fraud Class Action Result of Undisclosed Component Cost Increase and 14% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until July 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Calix, Inc. (NYSE: CALX) (“Calix” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 28, 2026 and April 21, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of Calix and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-calx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 28, 2026.

About the Lawsuit

Calix. and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On April 21, 2026, post-market, Calix reported its 1Q 2026 financial results, disclosing that non-GAAP gross margin declined 80 basis points sequentially to 57.2%. The Company further guided second quarter 2026 non-GAAP gross margin to approximately 55.8% at the midpoint, representing an additional sequential decline of 140 basis points, which management attributed primarily to increased memory component costs. In the accompanying earnings call, the Company’s Chief Financial Officer revealed that advanced purchasing had allowed the Company to avoid higher memory component costs during the first quarter, but that the advanced supply had run its course and the Company now faced market prices, and thus expected non-GAAP gross margin to decline between 50 and 150 basis points.

On this news, the price of Calix’s shares fell $6.93 per share, or approximately 14%, to close at $42.65 per share on April 22, 2026.

The case is Noor v. Calix, Inc., et al., No. 26-cv-04993.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

Kahn Swick & Foti, LLC

NYSE:CALX

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

Social Media Profiles
More News From Kahn Swick & Foti, LLC

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and Avenzo Therapeutics, Inc. Upon completion of the proposed transaction, pre-Transaction Rallybio equityholders are expected to own approximately 2.8% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, o...

Taylor Morrison Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taylor Morrison Home Corporation - TMHC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Taylor Morrison Home Corporation (NYSE: TMHC) to Berkshire Hathaway Inc. (NYSE: BRK.A; BRK.B). Under the terms of the proposed transaction, shareholders of Taylor Morrison will receive $72.50 in cash for each share of Taylor Morrison that they own. KSF is seeking to determine whether this consi...

Select Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Select Medical Holdings Corporation - SEM

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Select Medical Holdings Corporation (NYSE: SEM) to a consortium led by Select Medical executives and directors. Under the terms of the proposed transaction, shareholders of Select Medical will receive $16.50 in cash for each share of Select Medical that they own. KSF is seeking to determine whet...
Back to Newsroom